Favorable immune recovery and low rate of GvHD in children transplanted with partially T cell-depleted PBSC grafts

被引:3
作者
Seitz, Christian Martin [1 ]
Eyrich, Matthias [2 ]
Greil, Johann [3 ]
Schlegel, Patrick [1 ]
Feuchtinger, Tobias [4 ]
Bader, Peter [5 ]
Ebinger, Martin [1 ]
Schwarze, Carl Philipp [1 ]
Schlegel, Paul Gerhardt [2 ]
Schumm, Michael [1 ]
Handgretinger, Rupert [1 ]
Lang, Peter [1 ]
机构
[1] Univ Childrens Hosp, Dept Gen Pediat, Hematol Oncol, D-72076 Tubingen, Germany
[2] Univ Childrens Hosp, Dept Hematol Oncol & Stem Cell Transplantat, D-97080 Wurzburg, Germany
[3] Univ Childrens Hosp, Dept Hematol Oncol, D-69120 Heidelberg, Germany
[4] Dr von Haunersches Kinderspital, Dept Hematol Oncol & Stem Cell Transplantat, D-80337 Munich, Germany
[5] Univ Childrens Hosp, Div Stem Cell Transplantat & Immunol, D-60590 Frankfurt, Germany
关键词
VERSUS-HOST-DISEASE; BLOOD STEM-CELLS; MATCHED UNRELATED DONORS; CD34(+) PROGENITOR CELLS; LONG-TERM SURVIVAL; PERIPHERAL-BLOOD; BONE-MARROW; ALLOGENEIC TRANSPLANTATION; ACUTE-LEUKEMIA; RECONSTITUTION;
D O I
10.1038/s41409-018-0212-7
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Transplantation of peripheral blood stem cells (PBSC) from matched unrelated donors (MUD) is still associated with a significant risk for graft vs. host disease (GvHD), especially in pediatric patients receiving grafts from adult donors containing high amounts of T cells. Here, we present long-term follow-up results on 25 pediatric patients, (acute leukemia n = 15, NHL n = 3, CML n = 3, MDS n = 5), transplanted with CD34 or CD133 positively selected PBSC from MUDs supplemented with an add-back of 1 x 10(7)*/kg body weight (kgBW) unselected T cells resulting in a median T-cell depletion (TCD) of 1.97 log. A total of 24*/25 (96%) patients had primary engraftment. Early T-cell recovery was significantly improved compared to patients receiving CD34-selected grafts without T-cell add-back and similar to patients receiving unmanipulated bone marrow. GvHD incidence was low with 8*/4% aGvHD grade II*/III, no grade IV and 13% limited cGvHD. In total, 16*/25 (64%) patients are alive after a median follow-up of 10 years. Five-year event-free survival (EFS) was 68%, relapse probability 24% and transplantation-related mortality (TRM) 12%. Thus, in PBSC allotransplants from MUD, partial TCD with serotherapy and CSA*/MTX prophylaxis, can effectively reduce GvHD without hampering engraftment and immune reconstitution.
引用
收藏
页码:53 / 62
页数:10
相关论文
共 35 条
[31]   Long-term survival and late deaths after allogeneic bone marrow transplantation [J].
Socié, G ;
Stone, JV ;
Wingard, JR ;
Weisdorf, D ;
Henslee-Downey, PJ ;
Bredeson, C ;
Cahn, JY ;
Passweg, JR ;
Rowlings, PA ;
Schouten, HC ;
Kolb, HJ ;
Klein, JP .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (01) :14-21
[32]  
Sutherland H. J., 1996, Bone Marrow Transplantation, V18, pS1
[33]   The number of donor CD3+ cells is the most important factor for graft failure after allogeneic transplantation of CD34+ selected cells from peripheral blood from HLA-identical siblings [J].
Urbano-Ispizua, A ;
Rozman, C ;
Pimentel, P ;
Solano, C ;
de la Rubia, J ;
Brunet, S ;
Pérez-Oteiza, J ;
Ferrá, C ;
Zuazu, J ;
Caballero, D ;
Carvalhais, A ;
Díez, JL ;
Espigado, I ;
Martínez, C ;
Campilho, F ;
Sanz, MA ;
Sierra, J ;
García-Conde, J ;
Montserrat, E .
BLOOD, 2001, 97 (02) :383-387
[34]  
WAGNER JE, 1990, BLOOD, V75, P1370
[35]   Immunobiology of allogeneic hematopoietic stem cell transplantation [J].
Welniak, Lisbeth A. ;
Blazar, Bruce R. ;
Murphy, William J. .
ANNUAL REVIEW OF IMMUNOLOGY, 2007, 25 :139-170